Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bortezomib, Thalidomide, and Dexamethasone Versus Thalidomide and Dexamethasone for Response Rates in Multiple Myeloma Patients: a Retrospective Study

NCT06284395 is registered in ClinicalTrials.gov with Hospital General de Mexico as lead sponsor.

NCT NCT06284395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06284395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bortezomib, Thalidomide, and Dexamethasone Versus Thalidomide and Dexamethasone for Response Rates in Multiple Myeloma Patients: a Retrospective Study
Lead sponsor
Hospital General de Mexico
Phase
Observational
Overall status
Recruiting
Start date
November 20, 2023
Completion date
October 30, 2024
Enrollment
83 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

response, acute phase, survivorship